Skip to main content
. 2024 May 20;7:19. doi: 10.20517/cdr.2024.04

Table 1.

GI50 concentrations of pentoxifylline in two pairs of sensitive and MDR counterpart NSCLC cell lines

Drug GI50* (mM)
NCI-H460 NCI-H460/R A549 A549-CDR2
Pentoxifylline 0.96 ± 0.08 1.17 ± 0.17 1.23 ± 0.07 1.53 ± 0.04

*GI50 concentration (which causes 50% inhibition of cell growth) after 48 h of drug treatment (determined with the SRB assay). MDR: Multidrug resistance; NSCLC: non-small cell lung cancer; SRB: sulforhodamine B.